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Molecular typing and whole genome sequencing (WGS) information is used for (inter-)
national outbreak investigations. To assist the implementation of these techniques for tuber-
culosis (TB) surveillance and outbreak investigations at European level there is a need for
inter-country collaboration and standardization. This demands more information on molecu-
lar typing practices and capabilities of individual countries. We aimed to review the use of
molecular/genomic typing for TB surveillance in European Union and European Economic
Area countries in 2016; assess its public health value; and collect experiences on typing
data use for cross-border cluster investigations.
Method
A web-based questionnaire was provided to all TB National Focal Points. The questionnaire
consisted of three parts: i) Use and integration of molecular and genomic typing data into TB
surveillance; ii) Cross-border cluster investigation and international collaboration, and iii)
Perception and evaluation of public health benefits of molecular and genomic typing for TB
surveillance.
Results
Of 26 responding countries, 20 used molecular typing for TB surveillance, including nine
applying WGS. The level of integration into the national surveillance was heterogeneous.
Among six countries not using typing for TB surveillance, more than half planned its imple-
mentation soon. Overall, most countries perceived an added public health value of molecu-
lar typing for TB control. Concerning international cluster investigations, countries had little
experience and did not have standard protocols to exchange typing data.
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Conclusion
Our study shows a wide use of molecular and genomic typing data for TB surveillance in
EU/EEA countries and reveals that transition to WGS-based typing is ongoing or is consid-
ered in most countries. However, our results also show a high heterogeneity in the use and
integration of typing data for TB surveillance. Standardization of typing data use for TB sur-
veillance is needed and formal procedures should be developed to facilitate international
collaboration.
Introduction
Molecular typing of Mycobacterium tuberculosis complex (MTB) is increasingly used to
strengthen tuberculosis (TB) surveillance. 24-locus mycobacterial interspersed repetitive units
variable number of tandem repeats (24 MIRU-VNTR) has become a standard tool [1, 2]. Yet,
the transition to whole genome sequencing (WGS) is ongoing in the European Union (EU)
and European and Economic Area (EEA) [3, 4]. Due to its higher discriminatory power [5]
and potential to detect drug resistance [6], WGS is becoming a powerful tool to investigate TB
outbreaks [7–10]. Recently, national TB contact points and reference laboratories supported
by the European Centre for Disease Prevention and Control (ECDC) have used WGS-based
typing to detect and clarify cross-border TB transmission [11, 12].
A recent review of the European Reference Laboratory Network for Tuberculosis (ERLTB--
Net) [5], however, underlines that the appropriate role of WGS in TB surveillance remains to
be defined and further evidence on the technical capacity across EU/EEA is needed before
WGS-based surveillance for multidrug-resistant (MDR) TB can be operationalized [13, 14].
We have performed a questionnaire survey among EU/EEA Member States to i) review cur-
rent practices in application of molecular/genomic typing for TB surveillance and capacity of
transition to WGS-based typing; ii) explore the capability to use the typing in cross-border
cluster investigations; and iii) assess its added public health value for TB surveillance, and to
identify areas for future actions.
Methods
A web-based questionnaire (Acuity 4 Survey, Voxco) was developed. It was piloted amongst
five volunteering countries (Denmark, Italy, the Netherlands, Norway and Sweden) and there-
after adjusted.
The survey was conducted between September and November 2016 among TB National
Focal Points of all EU/EEA Member States. Participants were encouraged to consult with
other competent bodies in their country if needed. Countries not responding were followed up
with two reminder emails.
The questionnaire consisted of three parts: i) Use and integration of molecular/genomic
typing data into TB surveillance; ii) Cross-border cluster investigation and international col-
laboration, and iii) Perception and evaluation of public health benefits. The questionnaire
comprised 23 closed- and three open-ended questions. Data protection was guaranteed by the
Server architecture and the data protection concept of the RKI and approved by the data pro-
tection and legal departments of the RKI, resulting in a waiver for ethical review.
We performed a descriptive analysis of the collected data using Stata 14.0. Maps were gener-
ated using Regiograph (http://regiograph.gfk.com/).
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Results
Of the twenty-six responding EU/EEA countries (26/31; 84% response rate), 20 countries did
and six did not use molecular/genomic typing for TB surveillance (Fig 1).
Countries using molecular/genomic typing for TB surveillance
Of the 20 countries that used typing data for surveillance, 19 used them for national surveil-
lance and four also at sub-national level. Spain used typing data only at sub-national level
(Table 1). 24 MIRU-VNTR was used by all countries. Seven countries used exclusively 24
MIRU-VNTR and 13 combined it with either spoligotyping (4/20); WGS (5/20); spoligotyping
and WGS (3/20) or IS6110-RFLP, spoligotyping and WGS (1/20). Overall, nine countries
(Austria, Denmark, Finland, France, Italy, Norway, Spain, Sweden and UK) used WGS, ten
more countries considered its introduction (Table 1).
Of WGS-using countries, Austria used WGS as primary typing method (1/9) and five coun-
tries (Denmark, Finland, Italy, Norway and Spain) as secondary typing method to improve the
resolution within spoligotyping and/or 24 MIRU-VNTR clusters (Table 2). Sweden was plan-
ning to use WGS as primary typing method in September 2016, and England (unknown for
Wales, Northern Ireland & Scotland), Norway and Denmark from 2017. France was imple-
menting progressively the use of WGS as high-resolution typing tool and Italy also used WGS
for determination of drug-resistance.
All 20 countries typed multidrug and extensively drug-resistant (M/XDR) TB isolates using
24 MIRU-VNTR. Average estimated typing coverage in 2015 was 95% (range 53–100). All but
three countries (Bulgaria, Estonia and Germany) also systematically typed outbreak isolates
and 13 countries typed all kinds of MTB isolates, eleven with a coverage of� 90%.
Fig 1. Molecular typing for TB surveillance in European Union/European Economic Area countries in 2016.
https://doi.org/10.1371/journal.pone.0210080.g001
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WGS was used to type all MTB isolates in two countries (Denmark and Sweden); both M/
XDR and outbreak isolates in four countries (Austria, Finland, Italy and Spain); only M/XDR
isolates in France and only outbreak isolates in Norway. The UK was in transition from 24
MIRU-VNTR to WGS for all MTB isolates (Table 1). Three countries (Denmark, Finland and
Sweden) typed� 90% of their M/XDR isolates using WGS.
Where is typing performed?. All 20 countries had a National Reference Laboratory
(NRL) that performed molecular/genomic typing. Additional typing laboratories included
regional reference laboratories (2/20); peripheral level laboratories (2/20); clinical laboratories
(2/20); research institutes (1/20) and a commercial typing service provider inside the country
(1/20) or outside the country (1/20). All countries using WGS-based typing performed it in
their NRL. In France and Spain, WGS-based typing was also performed by a commercial typ-
ing service provider and peripheral level laboratories, respectively.
The estimated median timespan between a MTB positive culture and reception of the typ-
ing results by surveillance units was 30 days for both 24 MIRU-VNTR (interquartile range,
IQR, 14–60) and WGS (IQR 14–40).
Who is analyzing typing data?. Analysis of 24 MIRU-VNTR data to identify molecular
clusters was performed by the typing laboratory (11/20); jointly by typing laboratory and sur-
veillance units (7/20) or entirely by the surveillance unit (2/20).
Analysis of WGS data was mainly performed by the typing laboratory in Austria, Denmark,
Finland, Italy and Norway, and jointly by typing laboratory and surveillance unit in France
and Sweden, and by the TB surveillance unit in Spain. In England the analytical pipeline setup
was in progress.
Integration of typing data into TB notification databases. Sixteen of 20 countries inte-
grated the molecular/genomic typing data into the TB notification database on a case-based
level. This integration occurred mostly at national level (14/16) and in Ireland and UK also
Table 2. Overview of integration of WGS-based typing in TB surveillance systems in European Union/European Economic Area countries.















Austria M/XDR; outbreak 10 50 NRL Primary 15 Typing lab No Yes
Denmark MTB 20 100 NRL Secondary 14 Typing lab No No
Finland M/XDR; outbreak 10 90 NRL Secondary 30 Typing lab No Yes














NRL Secondary 40 Typing lab No Yes




















NA NA NRL Implementation in
progress.
NA Set up in progress No Yes
Com. typ. serv.: commercial typing service; MDR: multidrug-resistant tuberculosis; MTB: Mycobacterium tuberculosis; NRL: National Reference Laboratory; PLL:
peripheral level laboratories; RRL: regional reference laboratory; XDR: extensively drug-resistant tuberculosis; WGS: whole genome sequencing.
https://doi.org/10.1371/journal.pone.0210080.t002
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sub-nationally. In Italy and Spain, integration only occurred sub-nationally. Only Italy and
Spain integrated WGS results into a notification database (sub-nationally). Three countries
(Czech Republic, Germany and Portugal) did not systematically integrate them, one country
replied “unknown”.
Countries not using molecular/genomic typing for TB surveillance
Six countries (Hungary, Latvia, Lithuania, Luxembourg, Malta and Romania) did not use
molecular typing data for TB surveillance (Table 3). However, four of them considered its
implementation soon (Hungary, Lithuania, Luxembourg and Romania) and three of them
(Lithuania, Luxembourg and Romania) considered using WGS. Three countries (Hungary,
Latvia and Lithuania) had performed molecular typing (mostly 24 MIRU-VNTR) of MTB iso-
lates for research (3/6) or laboratory cross-contamination investigation (1/6).
Barriers for using molecular/genomic typing data in TB surveillance
Most countries (18/26) identified barriers for using typing data in TB surveillance (Table 4).
“Financial constraints” was the most common barrier; both among countries using typing (10/
20) and among countries not using it (5/6). Besides “financial constraints”, “human resources”
(8/20) was most frequently mentioned by countries using molecular typing, while “data man-
agement and analysis” (3/6) by countries not using typing.
As to specific barriers to WGS-based typing (Table 5), mainly “financial constraints” were
reported, (6/9 countries performing WGS and 11/17 countries not performing WGS). Coun-
tries using WGS also highlighted “human resources” (5/9) as significant barrier. Countries not
using WGS underlined “data management and analysis” (10/17) as relevant barrier. Six coun-
tries (including countries using and not using WGS) did not perceive WGS-specific barriers.
Most countries claimed that standardization of WGS data analysis and outbreak investiga-
tion should be improved and that collaboration and data sharing should be facilitated. Several
countries mentioned that countries with WGS capacity could support other countries without
capacity.
Table 3. Overview of M. tuberculosis molecular typing practices in countries that do not use molecular typing for
TB surveillance in European Union/European Economic Area countries.
Country Molecular typing use Molecular typing
methods




Hungary Research; Laboratory cross
contamination investigation




Lithuania Research 24 loci
MIRU-VNTR
Yes Yes
Luxembourg No None Yes Yes
Malta No None No NA
Romania No None Yes Yes
MIRU-VNTR: Mycobacterial Interspersed Repetitive Units - Variable Number of Tandem Repeat; NA: not
applicable; NRL: National Reference Laboratory; PFGE: pulsed-field gel electrophoresis; PLL: peripheral level
laboratories; rep-PCR: repetitive sequence-based-PCR; RFLP: Restriction fragment length polymorphism; RRL:
regional reference laboratory; XDR: extensively drug-resistant tuberculosis; WGS: whole genome sequencing.
https://doi.org/10.1371/journal.pone.0210080.t003
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Cross-border cluster investigation and international collaboration
Fourteen of the 26 responding countries had been contacted at least once by another EU/EEA
Member State to participate in cross-border cluster investigations; only seven countries (Aus-
tria, Germany, Ireland, the Netherlands, Slovenia, Sweden and UK) had actively approached
another EU/EEA country for international collaboration.
Six countries (Ireland, the Netherlands, Norway, Slovenia, Sweden and UK) had established
standard operational procedures (SOPs) to perform national cluster investigations but none
had a SOP for international investigations. Countries relied on the following legal basis for the
international exchange of patient information in cross-border cluster investigation: Decision




























Finland ✓ ✓ ✓
France ✓












Romania ✓ ✓ ✓ ✓
Slovenia ✓











5% (1/20) 10% (2/20) 35% (7/20) 40% (8/20) 50% (10/20) 10% (2/20) 5% (1/20)
Non-mol.
typing countries
0 0 17% (1/6) 50% (3/6) 17% (1/6) 33% (2/6) 83% (5/6) 17% (1/6) 17% (1/6)
1 Other: Not enough experience to use molecular typing data in routine surveillance
2 Other: Lack of an agreed policy on utilising typing data for tracing contacts routinely and investigating possible sources of transmission; Delay in receiving MDR/XDR
isolates from the peripheral laboratories to the Reference typing laboratory.
https://doi.org/10.1371/journal.pone.0210080.t004
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No. 1082/2013/EU of the European Parliament and of the Council (8/26) [15], the Interna-
tional Health Regulation and Implementation Act of the country (8/26), and their respective
national law (4/26). Half of the countries (13/26) did not know which legal framework
applied.
Eight countries reported barriers for cross-border cluster investigations, seven reported
that there were none, eleven did not know. Main barriers were: “different levels of integration
of molecular typing data” (6/8); “[lack of] standardization of molecular typing methodologies”
(5/8); “reluctance to share personal data of patients” (4/8) and “legal constraints” (4/8;
Table 6).






















Belgium ✓ ✓ ✓ ✓ ✓
Bulgaria ✓ ✓ ✓ ✓ ✓ ✓
Croatia ✓ ✓ ✓ ✓ ✓ ✓
Czech Republic ✓ ✓ ✓
Denmark ✓
Estonia ✓
Finland ✓ ✓ ✓ ✓
France ✓ ✓
Germany1 ✓ ✓ ✓ ✓ ✓
Hungary ✓ ✓ ✓
Ireland ✓ ✓ ✓
Italy ✓ ✓




Netherlands ✓ ✓ ✓
Norway ✓ ✓ ✓
Poland ✓
Portugal ✓
Romania ✓ ✓ ✓ ✓
Slovenia ✓
















41% (7/17) 59% (10/17) 23% (4/17) 53% (9/17) 65% (11/17) 18% (3/17) 12% (2/17)
1 Other: currently lack of standardization of method, cluster definition, nomenclature, service structure for rapid assessment and communication of information
https://doi.org/10.1371/journal.pone.0210080.t005
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Public health benefits
All countries perceived a public health benefit of using molecular/genomic typing for TB sur-
veillance for (Fig 2): 1. Detection of unknown transmission links (24/26, formally evaluated by
16 countries); 2. Improvement of contact investigation (24/26, formally evaluated by 13 coun-
tries); 3. Identification and investigation of high risk strains (23/26, formally evaluated by 14
countries) and 4. Detection of clusters across different regions (23/26, formally evaluated by 12
countries).
As to specific benefits of using WGS-based typing (Fig 2), 24/26 countries perceived a bene-
fit, two countries did not know (Bulgaria and Malta). The main benefits were: 1. Higher

































Denmark ✓ ✓ ✓ ✓ ✓ ✓ ✓
Estonia ✓
Finland ✓ ✓ ✓
France ✓


































0 0 0 0 0 0 0 0
https://doi.org/10.1371/journal.pone.0210080.t006
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discriminatory power (19/26); 2. Improved contact investigation (16/26) and 3. Untie potential
outbreaks (16/26). Of the countries using molecular/genomic typing, most (19/20) considered
that using WGS-based typing was beneficial, compared to two third (4/6) of the countries that
did not use typing. WGS-using countries mostly considered WGS useful because it provides
additional information, namely drug resistance.
Discussion
Our survey shows that most EU/EEA Member States use molecular/genomic typing data for
TB surveillance and the transition to WGS is ongoing. Our results also reveal substantial differ-
ences in the use and integration of typing data into national TB surveillance systems and iden-
tify financial constraints as the main barrier to a broader use, as well as limited experience in
cross-border cluster investigation and a lack of respective SOPs. Most countries recognized a
public health benefit of molecular typing and an additional benefit of using WGS-based
typing.
The implementation of TB molecular surveillance is highly heterogeneous in EU/EEA
countries in terms of the kind of typing laboratories, the selection of isolates, the coverage, the
analytical approach used, and whether typing data are integrated into TB notification data-
bases. In three countries typing results took� 240 days to reach the surveillance units, which
Fig 2. Added public health value of molecular typing (a.) and specifically WGS-based typing (b.) for tuberculosis in
European Union/European Economic Area countries. Numbers in bars indicate number of countries.
https://doi.org/10.1371/journal.pone.0210080.g002
Molecular and genomic typing for tuberculosis surveillance in 26 European countries
PLOS ONE | https://doi.org/10.1371/journal.pone.0210080 March 13, 2019 11 / 16
may limit the impact on TB control and is in contrast to the increasing speed of typing, e.g., in
view of forthcoming genomic typing using direct samples [16].
Almost half of the responding countries that do not yet use molecular typing for TB surveil-
lance, use it for other purposes such as diagnosis or research, and Hungary and Malta contrib-
ute to the ECDC MDR-TB molecular surveillance project while not using typing data for their
national TB surveillance [17]. In Malta MDR-TB isolates are typed by the Dutch NRL [18] and
in Hungary together by the Dutch and the Hungarian NRLs.
Overall, major barriers identified for using molecular typing data for TB surveillance were
financial and human resource related. Countries using molecular typing also identified the
“utilization of the data for TB control” as a barrier, e.g., clustering does not necessarily mean
recent transmission [19–21] and therefore linking typing data to detailed epidemiological
information of clustered cases is essential.
TB spread has an international dimension, as shown by the ECDC MDR-TB molecular sur-
veillance project [17, 18]. WGS is being increasingly used to detect and clarify international
outbreaks, such as an international MDR-TB cluster among asylum seekers that continues to
expand across different EU countries [12], and a XDR-TB cross-border outbreak [22]. Rapid
sharing of molecular/genomic typing data and epidemiological information between countries
is important. Another investigation of a MDR-TB cluster in Austria, Romania and Germany
using WGS [11] has demonstrated the need for establishing protocols for data sharing, which
is supported by our results and previous studies [23]. However, EU/EEA countries still have
limited experience on conducting cross-border cluster investigations and lack respective
SOPs. This can potentially hamper international cluster investigations and subsequent mea-
sures of transmission control.
The major barriers for international collaboration were related to the different levels of typ-
ing data integration and insufficient standardization of molecular methodologies and data
analysis. This may be even more complex when WGS-typing is used and exchanged given that
data interpretation is more dependent on laboratory protocols and analysis pipelines [5, 24].
Therefore, standardized laboratory methodologies, analytical approaches and terminology are
essential to ensure interchangeable among countries [25]. The finding that WGS-based typing
is currently mostly exclusively performed by NRLs represents an opportunity for developing
respective international standards before the laboratory network gets potentially more com-
plex [14]. In 2017, ECDC initiated a pilot project on the use of WGS for molecular typing and
characterization of M. tuberculosis in the EU and EEA. The project aims to standardize WGS
laboratory procedures and bioinformatic analysis and to provide access to WGS for EU/EEA
Member States that do not yet have capacity for WGS of M. tuberculosis [26].
None of the participating countries mentioned the quality and reliability of molecular/
genomic typing results as a barrier to international collaboration. Proficiency testing of MIR-
U-VNTR typing has shown that laboratories face challenges with the inter- and intra-labora-
tory reproducibility of results [27]. The 2016 ECDC facilitated external quality assessment for
24 MIRU-VNTR typing showed that four of the 16 participating laboratories did not reach the
threshold level for certification (unpublished data), which can critically compromise cluster
investigations.
Demonstrating the added public health benefit of integrating molecular/genomic typing
into TB surveillance systems remains challenging, [5] even though multiple scientific studies
emphasize the power of molecular typing to clarify TB outbreaks [28, 29] particularly using
WGS [7–10, 30]; monitor within country domestic transmission [31–33]; or identify high risk
strains [34]. In our survey, surveillance units recognize the benefit of typing data for TB sur-
veillance, especially for the detection of unknown transmission links and improvement of TB
outbreak and contact investigations.
Molecular and genomic typing for tuberculosis surveillance in 26 European countries
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Strikingly, the countries not using molecular typing in-country mostly have a high percent-
age of MDR-TB cases [35]. And in several documented incidents, molecular typing performed
abroad pointed M/XDR-TB transmission scenarios in these countries [11, 12]. This places
even higher importance on timely international collaboration and information exchange, as
well as on integrating these countries in molecular typing programs.
Previous economic evaluations of integrated molecular surveillance systems in England
and the Netherlands suggested that the contribution of molecular typing to improve contact
investigations is limited and the system was not cost-effective in the investigation period [36–
38]. A recent study has shown the limited power of MIRU-VNTR to predict MTB genomic
relatedness [39] but expects that the introduction of WGS-based typing may change this pic-
ture, given its higher discriminatory power and drug resistance detection [6, 40]. Further for-
mal evaluations specifying and comparing different typing methods are thus needed, since
different typing methods lead to different conclusions and demand different resources [40].
The area-wide introduction of a routine WGS-service by Public Health England offers a special
opportunity to evaluate the added value and the costs of WGS-based typing for public health.
Limitations
Our EU/EEA survey provides a general overview but may not replace in-depth technical
exchange on integrated molecular TB surveillance systems. Despite the high response rate
(84%), selection bias may not be entirely excluded, and our results may overestimate the cur-
rent use of typing for TB surveillance in Europe. Since this is a rapid evolving field, some coun-
tries might have advanced in the implementation of WGS-based typing since the survey was
performed, e.g., in the UK.
Conclusions
Our study shows a wide use of molecular/genomic typing data for TB surveillance in EU/EEA
countries and an ongoing transition to WGS-based typing. A high heterogeneity in their use
and integration stress the need for timely standardization of WGS-based typing procedures
and exchange of results, as well as administrative and legal frameworks and SOPs to facilitate
international collaboration. The knowledge of pioneer countries and the perceived and
observed public health benefits of molecular typing for TB control area favourable premise to
tackle remaining challenges.
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